<SEC-DOCUMENT>0001628280-24-033743.txt : 20240731
<SEC-HEADER>0001628280-24-033743.hdr.sgml : 20240731
<ACCEPTANCE-DATETIME>20240731160532
ACCESSION NUMBER:		0001628280-24-033743
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240731
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240731
DATE AS OF CHANGE:		20240731

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vanda Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001347178
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				030491827
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34186
		FILM NUMBER:		241161900

	BUSINESS ADDRESS:	
		STREET 1:		2200 PENNSYLVANIA AVE NW
		STREET 2:		SUITE 300E
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20037
		BUSINESS PHONE:		202-734-3400

	MAIL ADDRESS:	
		STREET 1:		2200 PENNSYLVANIA AVE NW
		STREET 2:		SUITE 300E
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20037
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>vnda-20240731.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:6d73cfcb-dd44-477a-96e9-ece478a38d7f,g:3bdb99eb-bff4-44e5-a8ab-100cae70794e,d:fa88c2d64f2341129ebff360daa7b230-->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vnda="http://www.vandapharmaceuticals.com/20240731" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vnda-20240731</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001347178</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-26">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vnda-20240731.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-31</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-31</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vnda:SeriesAJuniorParticipatingPreferredStockPurchaseRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-31</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ifa88c2d64f2341129ebff360daa7b230_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.292%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.292%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">July&#160;31, 2024</ix:nonNumeric> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.292%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">VANDA PHARMACEUTICALS INC.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.292%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:34.212%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.214%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-34186</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">03-0491827</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File No.)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">2200 Pennsylvania Avenue NW</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 300E</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Washington</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">DC</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">20037</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">202</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">734-3400</ix:nonNumeric></span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Not Applicable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Former Name or Former Address, if Changed Since Last Report)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.292%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"/><td style="width:2.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.972%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.942%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.815%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.943%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-19">VNDA</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Global Market</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-21">Series A Junior Participating Preferred Stock Purchase Right, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-22">-</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-23">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-24">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-bottom:1pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ifa88c2d64f2341129ebff360daa7b230_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;2.02.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations and Financial Condition.</span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;31, 2024, Vanda Pharmaceuticals Inc. (&#8220;Vanda&#8221;) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter ended June 30, 2024 (the &#8220;Earnings Call&#8221;). The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various statements to be made during the Earnings Call are &#8220;forward-looking statements&#8221; under the securities laws, including, but not limited to, statements regarding Vanda&#8217;s commercial products, plans and opportunities, as well as statements about Vanda&#8217;s products in development and the related clinical development and regulatory timelines and commercial potential for such products. Words such as, but not limited to, &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;goal,&#8221; &#8220;likely,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and &#8220;could,&#8221; or the negative of these terms and similar expressions or words, identify forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Important factors that could cause actual results to differ materially from those reflected in Vanda&#8217;s forward-looking statements include, among others, Vanda&#8217;s assumptions regarding the strength of its business in the U.S. and Vanda&#8217;s ability to complete the clinical development of, and obtain regulatory approval for, the products in its pipeline. Therefore, no assurance can be given that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements made during the Earnings Call should be evaluated together with the various risks and uncertainties that affect Vanda&#8217;s business and market, particularly those identified in the &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221;, &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections of Vanda&#8217;s most recent Annual Report on Form 10-K, as updated by Vanda&#8217;s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. The information contained in this Current Report on Form 8-K is intended to be considered in the context of Vanda&#8217;s filings with the SEC and other public announcements that Vanda makes, by press release or otherwise, from time to time. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information conveyed on the Earnings Call will be provided only as of the date thereof, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements made during the Earnings Call after the date thereof, whether as a result of new information, future events or otherwise, except as required by law.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9.01.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements and Exhibits.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Exhibits</span></div><div style="text-indent:9pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.918%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vnda8-k7312024exhibit991.htm">Press release of Vanda Pharmaceuticals Inc. dated July 31, 2024.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ifa88c2d64f2341129ebff360daa7b230_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:5.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 31, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VANDA PHARMACEUTICALS INC.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Timothy Williams</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy Williams</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, General Counsel and Secretary</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>vnda8-k7312024exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i86f84556ae8c419c8e5b56191e0da01e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><img alt="vandaq32019earningsca_imag.jpg" src="vandaq32019earningsca_imag.jpg" style="height:88px;margin-bottom:5pt;vertical-align:text-bottom;width:264px"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Revenues for Q2 2024 were $50.5 million, an increase of 6% compared to Q1 2024 and an increase of 10% compared to Q2 2023</font></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Financial Guidance reinstated for Full Year 2024</font></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> approved for the acute treatment of bipolar I disorder&#59; commercial launch initiated in Q3 2024</font></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> commercial launch in multiple sclerosis initiated in Q3 2024</font></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Tradipitant NDA review for gastroparesis ongoing&#59; PDUFA date of September 18, 2024</font></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Positive results for tradipitant second Phase III motion sickness study results announced in May 2024&#59; NDA expected to be submitted in Q4 2024</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; July&#160;31, 2024 &#8211; Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq&#58; VNDA) today announced financial and operational results for the second quarter ended June 30, 2024.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;2024 has been marked by the achievement of significant clinical development milestones and the expansion of our commercial organization to support the commercialization of Fanapt in bipolar disorder and Ponvory in multiple sclerosis,&#8221; said Mihael H. Polymeropoulos, M.D., Vanda&#8217;s President, CEO and Chairman of the Board. &#8220;The expansion of our commercial operations positions us well for future growth as we advance our clinical development pipeline with late-stage and early-stage assets.&#8221;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Highlights</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Second Quarter of 2024</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total net product sales from Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $50.5 million in the second quarter of 2024, a 10% increase compared to $46.1 million in the second quarter of 2023, and a 6% increase compared to $47.5 million in the first quarter of 2024.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net product sales were $23.2 million in the second quarter of 2024, a 4% decrease compared to $24.1 million in the second quarter of 2023, and a 12% increase compared to $20.6 million in the first quarter of 2024.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net product sales were $18.7 million in the second quarter of 2024, a 15% decrease compared to $22.0 million in the second quarter of 2023, and a 7% decrease compared to $20.1 million in the first quarter of 2024. The decrease relative to the second quarter of 2023 was the result of continued generic competition in the U.S.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net product sales were $8.6 million in the second quarter of 2024, an increase of 26% compared to $6.8 million in the first quarter of 2024. The acquisition of PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson &#38; Johnson Company, was completed on December 7, 2023.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss was $4.5 million in the second quarter of 2024, compared to net income of $1.5 million in the second quarter of 2023, and net loss of $4.1 million in the first quarter of 2024.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cash, cash equivalents and marketable securities (Cash) was $387.7 million as of June 30, 2024, representing a decrease to Cash of $6.5 million compared to March 31, 2024. </font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">First Six Months of 2024</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total net product sales from Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $97.9 million in the first six months of 2024, a 10% decrease compared to $108.6 million in the first six months of 2023.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net product sales were $43.7 million in the first six months of 2024, a 7% decrease compared to $47.0 million in the first six months of 2023.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net product sales were $38.8 million in the first six months of 2024, a 37% decrease compared to $61.6 million in the first six months of 2023. The decrease relative to the first six months of 2023 was the result of continued generic competition in the U.S.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net product sales were $15.4 million in the first six months of 2024. The acquisition of PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Janssen was completed on December 7, 2023.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss was $8.7 million in the first six months of 2024, compared to net income of $4.8 million in the first six months of 2023.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cash was $387.7 million as of June 30, 2024, representing a decrease to Cash of $0.6 million compared to December 31, 2023.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Operational Highlights </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Psychiatry Portfolio</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (iloperidone)&#58; Vanda initiated the commercial launch of Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of bipolar I disorder in adults in the third quarter of 2024, including the expansion of its existing sales force and the introduction of prescriber awareness and comprehensive marketing programs.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Milsaperidone&#58; Vanda expects to submit a New Drug Application (NDA) for milsaperidone (also known as VHX-896 and P-88), the active metabolite of Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of schizophrenia and acute bipolar I disorder to the U.S. Food and Drug Administration (FDA) in early 2025.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Iloperidone LAI&#58; Vanda expects to initiate a Phase III program for the long acting injectable (LAI) formulation of Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by the end of 2024. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> (tasimelteon)</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vanda has initiated a HETLIOZ LQ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> program in pediatric insomnia. Although the prevalence of insomnia in children is difficult to determine, it is estimated that 20-40% of children experience significant sleep problems.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1,2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There are currently no approved treatments for pediatric insomnia.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vanda continues to pursue FDA approval for HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of jet lag disorder and insomnia. Vanda is challenging the FDA&#8217;s rejection of Vanda&#8217;s supplemental New Drug Application (sNDA) for the treatment of jet lag disorder in the U.S. Court of Appeals for the D.C. Circuit. Vanda has accepted the opportunity for a hearing with the FDA on the approvability of the insomnia sNDA.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vanda&#8217;s lawsuit asserting that U.S. Patent No. 11,285,129 will be infringed by generic versions of HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> marketed by Teva Pharmaceuticals USA, Inc. (Teva) and Apotex Inc. and Apotex Corp. (Apotex) is currently pending in the U.S. District Court for the District of Delaware. Vanda announced in July 2024 that the District Court ordered that Vanda&#8217;s HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit may proceed.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vanda submitted a Marketing Authorization Application for HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and a Line Extension Application for HETLIOZ LQ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the European Medicines Agency for the treatment of nighttime sleep disturbances in Smith-Magenis Syndrome.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> (ponesimod)</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vanda announced in May 2024 that ownership of the U.S. NDA and Investigational New Drug (IND) applications for PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> had been transferred to Vanda from a Johnson &#38; Johnson Company. Vanda initiated the commercial launch of PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of relapsing forms of multiple sclerosis in the third quarter of 2024 including the deployment of a specialty sales force. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vanda expects to file IND applications with the FDA for PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the treatment of psoriasis and ulcerative colitis, in 2024. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Tradipitant </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The NDA for tradipitant for the treatment of symptoms of gastroparesis is under review by the FDA with a PDUFA target action date of September 18, 2024. Although the review is ongoing, the FDA provided a preliminary notice that deficiencies preclude discussion of labeling. Gastroparesis is a significant unmet medical need with the last treatment option approved over 40 years ago and an estimated prevalence in the U.S. of over 6 million individuals.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2024, Vanda announced positive results from the second Phase III study of tradipitant for the treatment of motion sickness. Vanda expects to submit an NDA for the treatment of motion sickness to the FDA in the fourth quarter of 2024. An eventual NDA approval of tradipitant for the treatment of motion sickness would significantly expand the addressable patient population, with approximately 30% of the U.S. population reported to suffer from motion sickness under ordinary travel conditions that include travel by sea, air and land.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Early-Stage Programs</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VPO-227, a CFTR inhibitor for the treatment of cholera, has received approval to proceed in a Phase I study in Bangladesh, a country where treatment of cholera remains a significant and unmet need. Vanda plans to initiate this study by the end of 2024.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Phase I clinical study for VCA-894A for the treatment of a patient with Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), an inherited peripheral neuropathy for which there is no available treatment, expects to enroll the patient in mid-2024.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Phase I clinical study of VTR-297 for the treatment of onychomycosis, a fungal infection of the nail, was initiated in April 2024. The study is over 75% enrolled and is expected to be completed in the third quarter of 2024.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VQW-765, an alpha-7 nicotinic acetylcholine receptor partial agonist, is currently in clinical development for the treatment of acute performance anxiety in social situations.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GAAP Financial Results</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss was $4.5 million in the second quarter of 2024 compared to net income of $1.5 million in the second quarter of 2023. Diluted net loss per share was $0.08 in the second quarter of 2024 compared to diluted net income per share of $0.03 in the second quarter of 2023.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss was $8.7 million in the first six months of 2024 compared to net income of $4.8 million in the first six months of 2023. Diluted net loss per share was $0.15 in the first six months of 2024 compared to diluted net income per share of $0.08 in the first six months of 2023.</font></div><div style="margin-bottom:6pt;margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024 Financial Guidance </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vanda reinstates financial guidance and expects to achieve the following financial objectives in 2024</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.666%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full Year 2024</font></div><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Objectives</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full Year 2024</font></div><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Guidance</font></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$180 to $210 million</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year-end 2024 Cash</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$360 to $390 million</font></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vanda has scheduled a conference call for today, Wednesday, July&#160;31, 2024, at 4&#58;30 PM ET. During the call, Vanda&#8217;s management will discuss the second quarter 2024 financial results and other corporate activities. Investors can call 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode number 1278669. A replay of the call will be available on Wednesday, July&#160;31, 2024, beginning at 8&#58;30 PM ET and will be accessible until Wednesday, August&#160;7, 2024 at 11&#58;59 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode number is 1278669.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conference call will be broadcast simultaneously on Vanda&#8217;s website, www.vandapharma.com. Investors should click on the Investors tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations. The call will also be archived on Vanda&#8217;s website for a period of 30 days.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">References</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Calhoun SL, Fernandez-Mendoza J, Vgontzas AN, Liao D, Bixler EO. Prevalence of insomnia symptoms in a general population sample of young children and preadolescents&#58; gender effects. Sleep Med. 2014 Jan&#59;15(1)&#58;91-5. doi&#58; 10.1016&#47;j.sleep.2013.08.787. Epub 2013 Oct 16. PMID&#58; 24333223&#59; PMCID&#58; PMC3912735. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Fricke-Oerkermann L, Pl&#252;ck J, Schredl M, Heinz K, Mitschke A, Wiater A, Lehmkuhl G. Prevalence and course of sleep problems in childhood. Sleep. 2007 Oct&#59;30(10)&#58;1371-7. doi&#58; 10.1093&#47;sleep&#47;30.10.1371. PMID&#58; 17969471&#59; PMCID&#58; PMC2266270.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Rey et al J Neurogastroenterol Motil, Jan 2012.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Turner M, Griffin MJ. Motion sickness in public road transport&#58; passenger behavior and susceptibility. Ergonomics. 1999&#58; 42&#58; 444-461.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Vanda Pharmaceuticals Inc.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X &#64;vandapharma.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS</font></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various statements in this press release, including, but not limited to, the guidance provided under &#8220;2024 Financial Guidance&#8221; above, and statements regarding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vanda&#8217;s plans for pursuit of FDA approval of tradipitant for the treatment of motion sickness, milsaperidone for the treatments of schizophrenia and acute bipolar I disorder, and HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatments of insomnia and jet lag disorder&#59; Vanda&#8217;s clinical development plans for the LAI formulation of Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatments of psoriasis and ulcerative colitis, VPO-227 for the treatment of cholera, VCA-894A for the treatment of CMT2S, and VTR-297 for the treatment of onychomycosis&#59; the prevalence of pediatric sleep disorders&#59; the regulatory status of the Company&#8217;s NDA for tradipitant for the treatment of symptoms of gastroparesis&#59; the prevalence of gastroparesis&#59; the commercial opportunity for tradipitant for the treatment of motion sickness&#59; and the impact of generic competition on sales of HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in future periods are &#8220;forward-looking statements&#8221; under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda&#8217;s forward-looking statements include, among others, Vanda&#8217;s ability to complete and submit to the FDA the NDAs for tradipitant for the treatment of motion sickness and milsaperidone for the treatments of schizophrenia and acute bipolar I disorder within the specified timeframes&#59; the FDA&#8217;s assessment of the sufficiency of the data packages to be included in the NDAs for tradipitant and milsaperidone&#59; Vanda&#8217;s ability to correct the deficiencies identified by the FDA with respect to the sNDA for HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of insomnia&#59; the outcome in the U.S. Court of Appeals of Vanda&#8217;s challenge to the FDA&#8217;s rejection of its sNDA for HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of jet lag disorder&#59; Vanda&#8217;s ability to initiate the Phase III program for the LAI formulation of Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by the end of 2024&#59; the accuracy of the estimates regarding the prevalence of pediatric sleep disorders&#59; Vanda&#8217;s ability to file the INDs, and initiate the Phase III studies for, PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatments of psoriasis and ulcerative colitis by the end of 2024&#59; the outcome of the FDA&#8217;s review of Vanda&#8217;s NDA for tradipitant for the treatment of symptoms of gastroparesis&#59; the accuracy of the estimates regarding the prevalence of gastroparesis&#59; Vanda&#8217;s ability to enroll patients and initiate the Phase I study for VPO-227 for the treatment of cholera by the end of 2024&#59; Vanda&#8217;s ability to enroll the patient for the Phase I study for VCA-894A for the treatment of CMT2S by mid-2024&#59; Vanda&#8217;s ability to continue to enroll patients and complete the Phase I study of VTR-297 for the treatment of onychomycosis in the third quarter of 2024&#59; and the ability of generic competitors to increase their share of the market for HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda&#8217;s business and market, particularly those identified in the &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221;, &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections of Vanda&#8217;s most recent Annual Report on Form 10-K, as updated by Vanda&#8217;s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">www.sec.gov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div><div id="i86f84556ae8c419c8e5b56191e0da01e_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VANDA PHARMACEUTICALS INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands, except for share and per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30<br>2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30<br>2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30<br>2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30<br>2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> net product sales</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,150&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,077&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,729&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,959&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> net product sales</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,708&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,979&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,761&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,595&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> net product sales</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,616&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,446&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,474&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,056&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,936&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,554&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold excluding amortization</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,733&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,499&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,173&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,273&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,661&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,647&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,815&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,884&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,474&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,399&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,559&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,503&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,752&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,770&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,620&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,923&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,317&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,417&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,146)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,867)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,381)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(863)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,630&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,459&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,201&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,983&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,516)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,592&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,180)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,120&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (benefit) for income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(998)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,516)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,348&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,518)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,664)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,772&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, basic</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,220,838&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,453,916&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,990,890&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,233,878&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, diluted</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,220,838&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,535,615&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,990,890&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,469,105&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div><div id="i86f84556ae8c419c8e5b56191e0da01e_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VANDA PHARMACEUTICALS INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30<br>2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31<br>2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,953&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,821&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,723&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,443&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,864&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,155&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,171&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,170&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439,180&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432,946&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,303&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,037&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,375&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,103&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,599&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,369&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,559&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventory and other</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,355&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,985&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651,371&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,440&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,598&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,460&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue allowances</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,193&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,237&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,791&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,697&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,005&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,006&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,059&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,827&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,855&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,530&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706,844&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700,274&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164,056)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,392)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,516&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544,910&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651,371&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,440&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate Contact&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kevin Moran</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President, Chief Financial Officer and Treasurer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vanda Pharmaceuticals Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">202-734-3400</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pr&#64;vandapharma.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jim Golden &#47; Jack Kelleher &#47; Dan Moore</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collected Strategies</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VANDA-CS&#64;collectedstrategies.com</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SOURCE Vanda Pharmaceuticals Inc.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>vnda-20240731.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:6d73cfcb-dd44-477a-96e9-ece478a38d7f,g:3bdb99eb-bff4-44e5-a8ab-100cae70794e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vnda="http://www.vandapharmaceuticals.com/20240731" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.vandapharmaceuticals.com/20240731">
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20240731_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20240731_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20240731_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.vandapharmaceuticals.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember" abstract="true" name="SeriesAJuniorParticipatingPreferredStockPurchaseRightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>vnda-20240731_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:6d73cfcb-dd44-477a-96e9-ece478a38d7f,g:3bdb99eb-bff4-44e5-a8ab-100cae70794e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="simple" xlink:href="vnda-20240731.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_2cbe04a1-7b1a-45c5-a7b1-ef0258f689d3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_DocumentInformationTable_2cbe04a1-7b1a-45c5-a7b1-ef0258f689d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_83fa72bc-0860-4eeb-b583-b7c9c19f50e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_2cbe04a1-7b1a-45c5-a7b1-ef0258f689d3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_83fa72bc-0860-4eeb-b583-b7c9c19f50e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_83fa72bc-0860-4eeb-b583-b7c9c19f50e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_83fa72bc-0860-4eeb-b583-b7c9c19f50e1" xlink:to="loc_us-gaap_ClassOfStockDomain_83fa72bc-0860-4eeb-b583-b7c9c19f50e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3b60a545-6cd0-4b00-887d-32760fa87f85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_83fa72bc-0860-4eeb-b583-b7c9c19f50e1" xlink:to="loc_us-gaap_ClassOfStockDomain_3b60a545-6cd0-4b00-887d-32760fa87f85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1d745fef-907a-4318-96ae-c6ef41946fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3b60a545-6cd0-4b00-887d-32760fa87f85" xlink:to="loc_us-gaap_CommonStockMember_1d745fef-907a-4318-96ae-c6ef41946fd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember_183ecff4-5729-4f03-b329-fd3232017be7" xlink:href="vnda-20240731.xsd#vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3b60a545-6cd0-4b00-887d-32760fa87f85" xlink:to="loc_vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember_183ecff4-5729-4f03-b329-fd3232017be7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d38acc62-d8d1-4ed7-9eb0-34512540de69" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_DocumentType_d38acc62-d8d1-4ed7-9eb0-34512540de69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9fe5d1ac-ff9b-417b-a4e8-e7d8d5b79ca1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_DocumentPeriodEndDate_9fe5d1ac-ff9b-417b-a4e8-e7d8d5b79ca1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c2f9b999-269c-49b2-b7b8-dc1718c2a735" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityRegistrantName_c2f9b999-269c-49b2-b7b8-dc1718c2a735" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1a189683-247e-44fd-92ac-57e091cf51b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1a189683-247e-44fd-92ac-57e091cf51b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f97da2c3-6111-4cac-b0a4-d3e3cb55abfe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityFileNumber_f97da2c3-6111-4cac-b0a4-d3e3cb55abfe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_30e2b084-7fb2-4291-bb82-e6a04be766f2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityTaxIdentificationNumber_30e2b084-7fb2-4291-bb82-e6a04be766f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c8a61ad7-20ed-46b2-aba0-06dadb9e6477" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityAddressAddressLine1_c8a61ad7-20ed-46b2-aba0-06dadb9e6477" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_f4408e27-71e6-4619-8677-d38f9e783f13" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityAddressAddressLine2_f4408e27-71e6-4619-8677-d38f9e783f13" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_eda0b193-7e66-492a-bb67-32a51ebf0773" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityAddressCityOrTown_eda0b193-7e66-492a-bb67-32a51ebf0773" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9d31ffad-dd04-4f93-8b76-cb1bcb062b0c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityAddressStateOrProvince_9d31ffad-dd04-4f93-8b76-cb1bcb062b0c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_80bf68ef-59fc-4a7a-b15f-04225d630eda" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityAddressPostalZipCode_80bf68ef-59fc-4a7a-b15f-04225d630eda" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_58feceaa-986f-4717-961d-15fd4658f78e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_CityAreaCode_58feceaa-986f-4717-961d-15fd4658f78e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d72e0bc4-653d-4c24-806e-43365f4e74a7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_LocalPhoneNumber_d72e0bc4-653d-4c24-806e-43365f4e74a7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_bb739226-8405-4d21-b8f5-7d1401c6c190" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_WrittenCommunications_bb739226-8405-4d21-b8f5-7d1401c6c190" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_18f3783f-99e2-4c6a-bd8f-a7404063f7db" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_SolicitingMaterial_18f3783f-99e2-4c6a-bd8f-a7404063f7db" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_f9fda9c2-497d-43ee-a948-6c10155e217a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_PreCommencementTenderOffer_f9fda9c2-497d-43ee-a948-6c10155e217a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_07b61210-4aca-433e-a2f6-93e7dd2d09b6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_07b61210-4aca-433e-a2f6-93e7dd2d09b6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_fd60158d-1ac1-4ff8-95fe-5d665ca0986b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_Security12bTitle_fd60158d-1ac1-4ff8-95fe-5d665ca0986b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_22415af6-b5b5-4307-8e77-e7eda1ca33a3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_TradingSymbol_22415af6-b5b5-4307-8e77-e7eda1ca33a3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_00fc91f7-223a-4ca8-b98f-a20c9ff07e64" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_SecurityExchangeName_00fc91f7-223a-4ca8-b98f-a20c9ff07e64" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_dd104069-649b-41ae-87c3-cf4e3b2e5078" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityEmergingGrowthCompany_dd104069-649b-41ae-87c3-cf4e3b2e5078" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_40d77e06-2f5c-40c0-8137-e3eaff5cfa42" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityCentralIndexKey_40d77e06-2f5c-40c0-8137-e3eaff5cfa42" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_dcd22459-1cf6-483d-8e0f-b71c8524b15f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_AmendmentFlag_dcd22459-1cf6-483d-8e0f-b71c8524b15f" xlink:type="arc" order="22"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>vnda-20240731_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:6d73cfcb-dd44-477a-96e9-ece478a38d7f,g:3bdb99eb-bff4-44e5-a8ab-100cae70794e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember_a9aef19b-620e-44a4-8d9e-528a42d5551d_terseLabel_en-US" xlink:label="lab_vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Junior Participating Preferred Stock Purchase Right</link:label>
    <link:label id="lab_vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember_label_en-US" xlink:label="lab_vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Junior Participating Preferred Stock Purchase Right [Member]</link:label>
    <link:label id="lab_vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember_documentation_en-US" xlink:label="lab_vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A Junior Participating Preferred Stock Purchase Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember" xlink:href="vnda-20240731.xsd#vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember" xlink:to="lab_vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4b750c9d-cf57-4117-a87e-c67be44bd351_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_e414d2d4-3e3f-4aa1-aa07-d288541992a8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_fa79b99d-b2aa-41d4-aa87-74de9f9e1289_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_2f7b4660-b57d-44a1-8031-8870fb5ba068_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_503f1e08-2d98-4160-a89f-b5fbcf7d21bb_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0556d4df-5115-4c13-8a3b-310112e31cbb_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_08180513-7c7c-432a-a9db-c8fc64c27b0c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_eda72dbe-084e-40d8-8beb-4e0ce58d3c89_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c9bdc92f-312a-4650-8744-472a4d77ac2b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_dd631709-3ed3-4199-bf83-7a4855125129_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_38f29a38-b698-4a9a-8364-01f2cef36c75_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_6618f28e-0baa-4f43-88d5-04f2522e1137_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_54a38223-466e-4cb6-bc55-da5d81084a23_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f7834f55-c527-43df-a897-7db097bef296_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_28734a02-6746-4450-b4e0-65d8838a32a7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_79c85d86-8648-4ed4-bc06-fe4fdf372bcd_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f7484eae-5a03-4cea-97fe-f92dc8a31b20_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_fd538b8f-6fba-4ea4-906b-ebb3d0a9e8de_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_739b9ec6-d458-4332-b16d-6438b9efcf7d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_80f5ecea-c398-417f-9e79-4ac4cc61dd33_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_82e70dcb-b35e-4bb7-93b9-7f93d64a462b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_25bbf89c-8a12-415d-a2f9-b86d82e318bd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_58c3430f-2087-4421-8cb7-fdf2037ac3f0_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c597e3c5-42da-4ba3-98f0-19bc52ba608f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7294a57c-bdec-4d48-a20f-1f799b395987_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8cfa5a0b-877a-43f1-8ee9-920eecd3bca0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_c2574926-e0e6-4981-8e34-5340fd37ac47_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e9e2bb6b-b5af-4d32-97d2-2bb75af63250_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>vnda-20240731_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:6d73cfcb-dd44-477a-96e9-ece478a38d7f,g:3bdb99eb-bff4-44e5-a8ab-100cae70794e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="simple" xlink:href="vnda-20240731.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_bbcdf765-3e86-4cb0-bd23-4ceeea7d99c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_2cbe04a1-7b1a-45c5-a7b1-ef0258f689d3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bbcdf765-3e86-4cb0-bd23-4ceeea7d99c9" xlink:to="loc_dei_DocumentInformationTable_2cbe04a1-7b1a-45c5-a7b1-ef0258f689d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_83fa72bc-0860-4eeb-b583-b7c9c19f50e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_2cbe04a1-7b1a-45c5-a7b1-ef0258f689d3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_83fa72bc-0860-4eeb-b583-b7c9c19f50e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3b60a545-6cd0-4b00-887d-32760fa87f85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_83fa72bc-0860-4eeb-b583-b7c9c19f50e1" xlink:to="loc_us-gaap_ClassOfStockDomain_3b60a545-6cd0-4b00-887d-32760fa87f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1d745fef-907a-4318-96ae-c6ef41946fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3b60a545-6cd0-4b00-887d-32760fa87f85" xlink:to="loc_us-gaap_CommonStockMember_1d745fef-907a-4318-96ae-c6ef41946fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember_183ecff4-5729-4f03-b329-fd3232017be7" xlink:href="vnda-20240731.xsd#vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3b60a545-6cd0-4b00-887d-32760fa87f85" xlink:to="loc_vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember_183ecff4-5729-4f03-b329-fd3232017be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_2cbe04a1-7b1a-45c5-a7b1-ef0258f689d3" xlink:to="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d38acc62-d8d1-4ed7-9eb0-34512540de69" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_DocumentType_d38acc62-d8d1-4ed7-9eb0-34512540de69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9fe5d1ac-ff9b-417b-a4e8-e7d8d5b79ca1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_DocumentPeriodEndDate_9fe5d1ac-ff9b-417b-a4e8-e7d8d5b79ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c2f9b999-269c-49b2-b7b8-dc1718c2a735" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityRegistrantName_c2f9b999-269c-49b2-b7b8-dc1718c2a735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1a189683-247e-44fd-92ac-57e091cf51b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1a189683-247e-44fd-92ac-57e091cf51b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f97da2c3-6111-4cac-b0a4-d3e3cb55abfe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityFileNumber_f97da2c3-6111-4cac-b0a4-d3e3cb55abfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_30e2b084-7fb2-4291-bb82-e6a04be766f2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityTaxIdentificationNumber_30e2b084-7fb2-4291-bb82-e6a04be766f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c8a61ad7-20ed-46b2-aba0-06dadb9e6477" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityAddressAddressLine1_c8a61ad7-20ed-46b2-aba0-06dadb9e6477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_f4408e27-71e6-4619-8677-d38f9e783f13" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityAddressAddressLine2_f4408e27-71e6-4619-8677-d38f9e783f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_eda0b193-7e66-492a-bb67-32a51ebf0773" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityAddressCityOrTown_eda0b193-7e66-492a-bb67-32a51ebf0773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9d31ffad-dd04-4f93-8b76-cb1bcb062b0c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityAddressStateOrProvince_9d31ffad-dd04-4f93-8b76-cb1bcb062b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_80bf68ef-59fc-4a7a-b15f-04225d630eda" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityAddressPostalZipCode_80bf68ef-59fc-4a7a-b15f-04225d630eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_58feceaa-986f-4717-961d-15fd4658f78e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_CityAreaCode_58feceaa-986f-4717-961d-15fd4658f78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d72e0bc4-653d-4c24-806e-43365f4e74a7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_LocalPhoneNumber_d72e0bc4-653d-4c24-806e-43365f4e74a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_bb739226-8405-4d21-b8f5-7d1401c6c190" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_WrittenCommunications_bb739226-8405-4d21-b8f5-7d1401c6c190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_18f3783f-99e2-4c6a-bd8f-a7404063f7db" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_SolicitingMaterial_18f3783f-99e2-4c6a-bd8f-a7404063f7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_f9fda9c2-497d-43ee-a948-6c10155e217a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_PreCommencementTenderOffer_f9fda9c2-497d-43ee-a948-6c10155e217a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_07b61210-4aca-433e-a2f6-93e7dd2d09b6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_07b61210-4aca-433e-a2f6-93e7dd2d09b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_fd60158d-1ac1-4ff8-95fe-5d665ca0986b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_Security12bTitle_fd60158d-1ac1-4ff8-95fe-5d665ca0986b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_22415af6-b5b5-4307-8e77-e7eda1ca33a3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_TradingSymbol_22415af6-b5b5-4307-8e77-e7eda1ca33a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_00fc91f7-223a-4ca8-b98f-a20c9ff07e64" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_SecurityExchangeName_00fc91f7-223a-4ca8-b98f-a20c9ff07e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_dd104069-649b-41ae-87c3-cf4e3b2e5078" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityEmergingGrowthCompany_dd104069-649b-41ae-87c3-cf4e3b2e5078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_40d77e06-2f5c-40c0-8137-e3eaff5cfa42" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_EntityCentralIndexKey_40d77e06-2f5c-40c0-8137-e3eaff5cfa42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_dcd22459-1cf6-483d-8e0f-b71c8524b15f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_8720e1b7-987a-44fe-baf1-b1be9541985c" xlink:to="loc_dei_AmendmentFlag_dcd22459-1cf6-483d-8e0f-b71c8524b15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>vandaq32019earningsca_imag.jpg
<TEXT>
begin 644 vandaq32019earningsca_imag.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M^RO?-WL^7]FN]]W Z;&SMY)I#YZ8T+D"O$D"@'F:#IFYGCM;=[F7^SC0L?L
MKUJY[NW-D]Z;IW%N[,R>7*[FS>3SN08$E!592LFK)8X@WZ((6ET1J.%10
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MCNH:K9M5U#L[?$LN^-G9O/9K^-9[-[NQ]<JUV/W=@X!1"#!P^./PEE8L2QN
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M6FE2 :T!-:5(%<<*CSZJG[DG_E&]*YRNZ_[0^1/777^^<94+C\OA!W&,EN_
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M[^MG,O[GV]Z[%MS,BT.))N$LGH0M/#C.<!F4TDZV6/Y%W\OA/AG\7:3L3?\
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MH>NC=K=6]]:QWMFZR6DR*Z.IJK(P#*P/F""".E![9Z?ZT%/^%+7_ &\4PO\
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M9]BN7"U[8KZ-HB1Z)<Q*T4I/E^G&OJW4BV.U;'S%$;GE'<[6]C J4UC6H_I
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MTY*13T'!@/TW/^F4:"3@:4'%NLP?NV\Z>-:S\CWS_J0UGMJGBC']:,?Z5B)
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M6+41%_LIE$J^T_)G]:-_%W>I79K(AY*C#O\ Z''\P2-3C^%=)IJ'4*^]W/\
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M@:>?_"EK_MXIA?\ Q7#K3_WJ>Q_>2OL7_P J4_\ SW2_\<BZQ$^\A_T\)/\
MI70_\?FZVS/Y0O\ V[2^'/\ XB#'?^[;+^\=O<G_ )7K<_\ GI/^!>LJ_:7_
M *=OL_\ SR#_ (\W5C_L$=2+U47_ #2/Y3'4O\P_93[@Q@Q/7/R6VKC*B/8W
M:L./1(=Q004TK46Q>S31P-6YG:,U45^WJ@LU=A79I:8/&]12U,C\@>XNX\EW
M7@OJGV*1OU(J_#G,D5<*].(PK\&H0K+$WN=[4[5[@V7U$>BWYDB4^%/3XP!B
M*:@JT9/!LM&:E:@LC:1_5O;GS1_D_?+#,TL%'D^M^S-GUM-B^Q.LMS/4UVP>
MR]M?NS45+G:3&5\..W9M?)TE4]1BLI15'D@,HGHZB.2Y]Y4[AMO*_N5RZK$K
M/82@F.5:"2)O,J2*HX(HZ,,THP(ZPMVO=N<O:/FIT4-;;E"P66%ZF*9/(,%(
M$B,#5'4U%=2,#UOV?R__ .8CT5_,*ZICWUU?7_P+>^!AHZ;L[J3-UM*^[M@Y
MJ>%"[,D?B.=VE7SZ_P"&YB&)(*Q%*2)!51STT.'_ #CR7NW)FX_27XUVKDF*
M90=$B_\ /KC\2$U'D2I#'/#D+W!V/W VKZ[;&T7J ":!B/$B8_\ 'HR?@D H
MPP0K!E74\_X5 ?\ 9?747_BH&P?_ '\_?_O(?V$_Y4^Y_P"EE)_U8M^L5OO,
M_P#*^6G_ $J(O^TBZZV;/Y)O_;KCXC?^&AO+_P!^KOWW!'NG_P K_N7_ #53
M_JU'UDI[+_\ 3L=I_P":,G_5^7K1T_F\_P#;RWYC?^)@R7_NJQ/O*_VW_P"5
M%VS_ )YA_A/6$WNU_P!/(WC_ )ZS_P =7KZ/7QZ_YD%T=_XA_K3_ -XO"^\(
M]Z_Y+%W_ ,],O_'VZZ)<O_\ )!LO^>2'_JVO0P>RSHWZ][]U[KWOW7NN$DD<
M,<DTTB111(TDLLC*D<<:*6>21V(5$102238#WL DT''K1( J< =?*8Z;_P!_
M5\NNJ_X#_E_]Y/D=L?\ @O\ RB_>_P 8[-Q?\._X&_;_ &_W'W"?YWQZ+^K3
M8VZ$[G_B_+=QXV-%C)J\Z:8C7A6M*>77+79_\:YMM? [O$W&/3Y5U3+3C2E:
M^=/GU]17O'N?8'QVZB[![N[2S,>!V#UIMJOW/N+(/9IFIZ15CI,;CX"RM6YG
M-Y&:&BH:9/W*JMJ(H4!=U'O 7:=KO-ZW*':MO77>3R!5'S/$GT515F/DH)/#
MKIOO>\V'+VTW&];HXCL+:,NY^0X #S9C15'%F( R>OFR]H[Q^3'\W3YS9G+[
M7VU6;K[4[CS=;1; V%!E*>+$;'V#MJ@K:S#;;BRV4EH,3B<#M+;5$\U;62FF
MBJ:LU%5(//4OJSBV^VV+VWY36.XD$>WVR R24-9)&(#-05)9V-%45(%%&%ZY
MR[G><R>[/.[RVT9EW2\<B*+4-,42 E4U-156- 2S&@+:F/<QJ>3;?\DG^<WL
MW&_P;:&W\CM3$">6J_A6V_DQLW!8W[J<()ZG['%[\I:7SS"-=;Z=3:1<\>PI
M/[J>V%T_BW+K))2E6M78T]*F,GH;VWLM[Q6<?@VD;10UKI2\C45/$T64"O3_
M /\ #.G\\3_CKO#_ -*QV]_]L3VS_KF>U/\ PK_LD;_K7T__ *T/O9ZS?]ER
M?];>FG._R5?YTVZ,55X+<V*S6XL'7B):[#9WY/[2R^*K5@GBJH%J\=D-_5%)
M4B&I@21 Z-ID16'(!]N1>Z7M=;R":!E24<&6U<$>6"(P1C'34_LS[RW41@N5
M>2!N*M>QLIH:BH,I!R ?MZKSS6S/EK_*A^7>P\KN_;T_67>75==MWL/ 0G)T
M>9V_N7;N5BFBFIX\SMS(3XW<6T=T8TUV'RD=/4FZFKI)"DJ.JC.*ZY<]P^6Y
MH[9Q/M-P&C;!5E8>>EA570Z72H_A85!'4?S6?-?M7S;!+=QFVWNU9)4[@R.C
M5J-2$AXW&J-P#_&AH0:?1]^(WR=Z_P#F+\>NM?D+UM4+_ M^X.*IR&&DJ(Y\
MCM'=-$QH=U;-S.@)IR>V\W!-3L^E4J(E2HBU0S1NV$?,>PWG+.]3[+?#]:%Z
M!O)T.4=?DRT/R-0<@]=$N4^9MOYOY?MN8-M/Z$Z5*UJ8W&'C;^DC CYBC#M(
M/1D?9'T(^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K7V_X4
M9_%?<G?'PNPO;.RL?59?<7QCW=5[YS.,HXIJFIGZQW)C4PN_*ZFI8%9I)-O5
M-)B\I4.?1!C**KD/"^YD]D^8(-HYH;;KI@L%_&(U)P/%4ZHP3_2!=!ZLRCJ
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M%\].'8?Q:/-3U)'W=.0/IX&Y\W-/UI0T=H",A/ADF%>!?,:'CI$G%7!Z2O\
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MC);34Z02305-!0$GCT8OV2="'KWOW7NO>_=>Z++\JOA]\>_FCUQ+UA\ANO\
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MZ57B: DGT  !))(  ))IUK==VV[8["3=-VF2"PB +.W 5( &*DDD@  $DD
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M,Y\(_P#LHS^9Y_XM_M3_ .!>Z']D/-7_ "1-A_Z5K_\ :5<=";DO_E8>9O\
MI;I_VA6O2*_EXTL,7PV[Z6EIHHWJ?DG\^&D6GA5&GF7Y ]L4L3.(U!ED6G@C
MC4FY"(JC@ >U7.C$\S6>HX%CM_\ VCPG_9Z1>WR <GWX4"IW+=.'G_C4X_P
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M_P !SVW[0<N_\JGS#_SS6G_:;#T9<U?\KORM_P ]=[_W;Y^O?S9O^R&M^?\
MB7_B#_\ !C=!^_>W7_*V0_\ /->?]H5QU[W5_P"5(G_YZ[#_ +N%KT&G<_:_
M5?Q\_FG;&[*[ZWMM+J38.]_@EN'K;9/8_9&6QVU-DUF^\3W[B=TY_:$.\LY+
M28+%YL[<JJ6L:">H@,\"J1J*6"[:]NW#>?;^6QVB*2YO(MW65XH@7<1FW**^
MA:L5U K4 T/V]%V\[KM>P>Z$&Y;[-%:6$^QO#'-,P2,RK=*[1^(U%5M!5J$B
MH]:=#3O;YM?RZNQ=P=/=>UO>?Q_[\W7NONGKJFZKV9UQN?:?>>X,;VK09V'(
M[)WFF&V%5[IKMI0[1RE.*U\]4I2TF+CC:62=%#'V5VO*O.ME#<WJVEY9V\=K
M(97D1X%,16CIJD"!]8[?#%2_  ]'-[SI[>[A/9[>]]87]U+>PB".%TN7$X8&
M.33$7,?AL-1E;2J 5+ =$]^2]+\BOGO\D<?M#XV4?267^/?P<[2QM?V&_?-3
MOW_1IW=\G\;B*NJI-H14G7U+/7;EPWQS-?1UE;!--#1/N6I6&>.H%'I EV)M
MEY0V-KG?#=+O.[6Y$?TXC\6"U) +UD-%:YHRJ0"WA"H*ZN@CS(O,//?,2VG+
M@LGY?V2Z!E^J,O@W-Z%)$=(@2ZVE59@2%\8@,&T4Z?O@P.[/@WVU'\,ODLG6
M&.Z^[]RW87:'Q"R?4-7NRHZQV5N*/)UFZ.TOC'CWWK24><PJT--DCN3:]',)
M8WH7R,$=3*\"PQM<V?NKFS;OZS[%]0UY9K'%>"8()76@2*Z.@E6J1X4K"AU:
M"5 -2_R1^^N2=V_J=S)]*NWW[RS6!MS(88WU%Y[,>( RT!\:%34%?$4,2H41
M^B?E_P#%OX[?*G^9/MCO;OWJKJ7<6<^5.U,]A\+OW>6'VWD<EA3\:ND,>,I1
MTN1J899Z(UU%+%Y%!7R1L/J#[WNW+6_[UR_L=QM%G<7,*;>ZEHT9@&^JG-"0
M.-"#3Y]5V/F[ECE[FCF.VWR_M;2X?=$95ED5"5^CMAJ )%14$5]1T+'SF[D^
M,G??P4W-V9@>WZS<W4>$[7Z=J3W5\?Y=H]CGJC>.TNX=AY/%;]S>.R=3/MO(
M;8Z\S9H\AN&DK.3A?*RJ&:-_9=RGMF_;1S;'836PCW)[>8>!<:XO&1X9 8U(
M&H-(NI8R/QT^?1KSOO'+6^\CR[E!=F7:4NK<_46OAS>!)'<1%96#$H4B;2\J
MM_H=3Z'HIO<_RC@H>E>R:U/YT?P/[2,77VXF?KG)=5=&;E7LF%\+4)/L7(;8
MVAW[+N:L7>D#MCI8Z*DDGB^Z+"!]!B(CVO8"^Z0*>5]WM_UE_5$LZ^%W#]0.
M]OI&CX@6(!IQ%:]!3>>9UCV:Y<<Y;%=4MW_1:"V?QNTUB*1W6L^(.PA5)&JN
MDTIU<?\ %G.Y+='QB^.6YLSLK&]:Y?<70_4.=RO7.&QM9A</L#)9?K[;V0KM
ME8K#Y%Y<AB<;M6JJ&H8*:=FF@B@5')92?<9<P0I;[]?012M/&EW,HD8AFD D
M8!RPP2X&HD8)-1U,'*\\EURUMUS-"MM-)8P,T*@JL1:)"8U4Y4(3I .0!0YZ
MJ9^7G_,V?YR?_C(' ?\ O-?,+W(G+?\ R3N6/_%E;_CUEU%/-O\ R5></_%1
M3_CFX=6_?'K_ )D%T=_XA_K3_P!XO"^XWWK_ )+%W_STR_\ 'VZEOE__ )(-
ME_SR0_\ 5M>J!\M5X?:70N1[$W)%%0=:=/\ _"@KM'L/LW.RT;3X/8^P<)\F
M-_XNHW9G8H8I?M,!@LQEZ RSB,K2ZED.E4++,$:R7.[K909OKGDV*.):]TDC
M6L9"+ZLRJU!Y\//J!Y7AM-B;<+D:=ML^?II9FI58XEO)5,C>BJS+4T[<'RZM
MMWG_ #%?Y<\.R=S5FY?F-\4=Q[9;;F4.=V[0]U]8;OR6<PM103)D,/#LO%;B
MR>;W!49&CD:$T$5)--/K,?C))'N.;7DKG8W4:P;9N*3ZQI8P2H%8'#:RH5:'
M.HD <:]2O>>X7MX+*1[G>-JDMO#;4@N89"RD97PU=F<D8TA23PIT-O0?:'1>
M[-M8#8/2=5C<5C-B=2]+[AH>M*?!9#:>3ZZZP[%VI4U73]!DMHY*@Q]7M:&K
MVUMR>&GQ\L<<](*%X9(XVCT^RK>+#=K:=[S=0S237,ZF4L'$DL;@3$."0]&8
M$L"0=0()KT=;%N>QW=M'8;*52."TMW$(4H8H9D)MP8R 4JB$!" 5TD$ CH?O
M9/T?=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=1JRBH\C25%!D*2FKJ&LADIZNBK((JJDJJ>52DL%13SJ\,\,
MB$AE8%2#8CW969&#H2'!J",$?8>JNB2*4D 9"*$$5!'H0>/2)VUU1U;LS('+
M;/ZUV!M3*F%Z<Y/;6S=NX+(&GEMY(#6XO'4M289+>I=6D_D>U4^X[A=)X=S/
M-)'6M&=F'["2.D5MM6UV<GBV=M!%+2FI(T4T]*J >E_[1]+^O>_=>Z][]U[K
MWOW7NO>_=>Z][]U[J-645'D:::BR%)35U'4H8ZBDK((JFFGC)!*303*\4J$C
MZ,"/=E9D8,A(8<",'JKHDBE) &0\014'\CU)]UZMU$FH*&HJ:.MJ*.DGK,<9
MVQ]7-3PRU-"U5$8*EJ.=T:6F-1 =$A0KK3@W'NP=U4J"0K<17!IPKZTZJ41F
M#L 76M#3(K@T/E48-.LM13T]93STE7!#54M5#+3U--41)/3U%/.C1303PRJT
M<T,T;%65@59201;WI6*D,I(8&H(\NMLJNI1P"I%"#D$'R/7&.DI8JBHJXJ:G
MCJJM85JJF.&-*BI6F5UIUJ)E423+ LC! Q.D,;6O[\68@*2=(X#TKQIUH*H8
ML -1XGS-.%?LZYS0PU,,M/4113T\\4D,\$T:RPS0RJ4EBEB<,DD4B,0RD$$&
MQ]^!*D,IHPZV0&!5@"I&1UA6@H4JEKDHJ1:U:04"UBT\*U2T*R>9:):@()12
M"4:A'?1JYM?WO6Y702=%:TKBOK3U^?6M"!M8 UTI6F:>E?3Y=99Z>GJ51:F"
M&H6*:&HC6>))5CJ*>19J>=!(K!)H)5#(P]2L 00?>@S+\)(Q3\CULJK88 T-
M?S' _EUP@HJ.EDJIJ:DIJ>:NF%16RP01125E0L4<"SU3QJK5$RP1*@9R6"*!
M>P'O99F #$D 4'R^SK2HBDE0 6-30<3PJ?7'7J6BHZ&-H:&DIJ.%YIZAXJ6"
M*GC:HJ97GJ9V2%45IJB=V=V(U.Y)))/OS,SFKDDTIG/#AUY41!1  *DX%,G)
M/YGCUX45&LL4XI*83P?=>&801"6'[Z19JWQ2!-<?WDR!Y;$>1@"UR/?M34I4
MT-/Y</V>7IU[0E0U!J%?+UX_M\_7J3[KU;IMJ,-AZO'RXFJQ6-J<7.[238VH
MH:6;'S2-5?>M)+1R1-3R.U;^\25),OK_ %<^[B617\1682#SJ:\*<>/#'V=-
MM#"\9B=5,1X@@$<:\.''/VYZ;L=L_:6(JDKL3M;;F,K8@ZQUF.PF,HJJ-9$,
M<BI44U+%,@DC8JP!Y!L?;CW-S(NB21V3T+$C]A/3<=I:1-KBBC5QYA0#^T#I
MXKJ"AR=+-0Y*CI,A15 5:BCKJ>&KI9U5UD59J>=)(90LB!@&!L0#^/;2.\;!
MT)5QY@T/[>GG1)%*2 ,AX@BH/Y'IDH=E[.QE5#78W:>V<?6T[,U/64."Q=)5
M0,R-&S0U$%+'-$S(Y4E2+@D>W7NKF12CR2,A\BQ(_97IA+.SB8/'%&KC@0J@
MC\P.I.5VOMK.31U&;V[@LQ40Q>&*?*XF@R$T4.IG\4<M73S.D6MR=((%R3^?
M=8YYXAIB=U4^A(_P=6EMK:<AIHT=@.+*#_A'7L5M?;6#FDJ,)MW!8>HFB\,L
M^*Q-!CYI8=2OXI):2GA=XM: Z22+@'\>_23SRC3*[LH]23_AZ]%;6T!+0QHC
M$<54#_ .G2:BHZB>DJIZ2FGJ:!Y9*&HF@BDGHI)X7IIWI)G5I*=YJ>1HW*$%
MD8J>"1[H&8 J"0IXCU\\^N>G2B,P9@"R\#3(K@T],8ZYU%/3U<+T]5!#4P2:
M?)!41)-"^AE==<<BLC:74$7'! /O2LRG4I(/RZVRJPTL 5^?4;)8K%YFF-%E
M\;096C9TD:DR5'3UU,9(R3'(8*J.6(NA/!M<?CW9))(FU1L5;U!(/\NJ2113
M+HE563T(!'[#TW8S:>UL+4FLPVVMOXFK,;0FJQF&QU!4F%RK/$9Z6FBE,;L@
M)6]B0/Z>[R7%Q*NF5W9?0L2/YGJD=K:PMKACC1Z<0H!_:!T\4U+2T47@HZ:G
MI(/)/-X::&."+S54\E54R^.)43R5%3,\DC6N\CEC<DGVTS,QJQ)/S^6!^P8Z
M=550:4 "U/#'$U/[3D_/KE-3T]1XON((9_!,E1!YHDE\-1%?QSQ:U;QS1ZCI
M8687X/OP9E^$D5%/RZV55J:@#0U_/UZ3]=LO9V3JIJ[);3VSD*VH96J*RNP6
M+JZJ=E18U::HGI9)I65$"@L38 #V\EU<QJ$2214'D&('[*])WL[.5B\D4;.>
M)*J2?S(Z=,=AL/B*1Z#$XK&XNAD>222CQU#2T5(\DJJDLCT]-%%"SR(@#$BY
M  /MMY9)&UR,S/ZDDG]IZ=CAAA31$JJGH  /V#IGI]B[(HZB"KI-G;5I:JEF
MBJ*:II]O8B"HIZB!UEAG@FBHUDAFAD4,K*0RL 0;^W6N[I@5:60J10@L<_SZ
M96QLD8.D,08&H(1001YC'2J]I^E74.?'8^J^Y^ZH:.I^]HSCJSSTT$WW>/;S
M7H:GR(WGHS]Q)>)[IZVX]1O8.ZTTDBAJ,\#ZCYXX]4:.-JZE!U"AJ!D>A]1D
MXX9ZDQQQPQQPPQI%%$BQQ11JJ1QQHH5(XT4!41%   %@/>B234\>K  "@P!U
MB^TI=%1']M3^.K:1JN/PQZ*II8UBE:H73IF:2)0K%KW4 'CW[4U0:FHX?+[.
MM:5H104/'Y_;TFX=A[&IIHJBGV9M."H@DCF@GAV[AXIH9HF#Q2Q2I1J\<D;J
M"K @@BX]OF[NV&EI9"#_ $C_ )^DXL;)2&6&(,#@Z%_S=*..BHX:FIK8J2FB
MK*Q*>.LJXX(DJ:N.D$HI4J9U42SI3"=_&&)":VM:Y]LEF*A23I' >0KQI]O2
M@(@8N  YI4TR:<*GSI4TZD^Z]6Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
(7NO>_=>Z_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140239289418304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 31,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VANDA PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">03-0491827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2200 Pennsylvania Avenue NW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300E<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Washington<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">734-3400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001347178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VNDA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember', window );">Series A Junior Participating Preferred Stock Purchase Right</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Series A Junior Participating Preferred Stock Purchase Right, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">-<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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ME7QB]5"XE MKCJ#=];H]C&SGY0 WY!!2&1?IO$GHO)8'%V@<I,K4?=R"K2O
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MA H#E&^J%977DHHM)]W1ZTSO'R:/6D;KW$JY]_!*MAQSCG^T_ %02P,$%
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MO-9.&G_FB^$_7G\!4$L! A0#%     @ KX#_6 =!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "O@/]8
MHA,/<^\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " "O@/]8F5R<(Q &  "<)P  $P              @ '-
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( *^ _U@MY(2F 04
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M2P$"% ,4    " "O@/]8)!Z;HJT   #X 0  &@              @ %N$@
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "O@/]899!Y
MDAD!  #/ P  $P              @ %3$P  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     "0 ) #X"  "=%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="vnda-20240731.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="vnda-20240731.htm">vnda-20240731.htm</File>
    <File>vnda-20240731.xsd</File>
    <File>vnda-20240731_def.xml</File>
    <File>vnda-20240731_lab.xml</File>
    <File>vnda-20240731_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "vnda-20240731.htm": {
   "nsprefix": "vnda",
   "nsuri": "http://www.vandapharmaceuticals.com/20240731",
   "dts": {
    "inline": {
     "local": [
      "vnda-20240731.htm"
     ]
    },
    "schema": {
     "local": [
      "vnda-20240731.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "vnda-20240731_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "vnda-20240731_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vnda-20240731_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 1,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 30,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 26
   },
   "report": {
    "R1": {
     "role": "http://www.vandapharmaceuticals.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vnda-20240731.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vnda-20240731.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "vnda_SeriesAJuniorParticipatingPreferredStockPurchaseRightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vandapharmaceuticals.com/20240731",
     "localname": "SeriesAJuniorParticipatingPreferredStockPurchaseRightMember",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Junior Participating Preferred Stock Purchase Right",
        "label": "Series A Junior Participating Preferred Stock Purchase Right [Member]",
        "documentation": "Series A Junior Participating Preferred Stock Purchase Right"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001628280-24-033743-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-033743-xbrl.zip
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MHM&PZP<51"0%BJ5!/K'!T08<RXOO&W6[X2S_Y-BN>E]6XR7Y1T/"2IR65!]
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M4!@E5+L.$3+]-0AII-= '7XHTA[$<@8BY,%<ERGCJUT<U!8X%(1G(7 "  Q
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M5'74^Y,K\?&7%B4+54U#A_D)2VDR?F5YN7)7!&/XKY\.PI/_!U!+ P04
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M7/A.E1S):Q_)T16-7/H/P*<)]P. /@)@7(#:&(S=D0Z >IL(6$@1_O!] F-
M&DHQY9_4SL" +EV8G\^(I:NI50L#VV>H5C^1NPCX#AC*X'BBX1=82&>8BGQ]
M#NIP)NY%<.CR+NPLVC9A0-QCXL(-G@CD/3!+%L4"*$7N'PX!- !S1!J" 402
MYD]%$?:HS_^56XPT$B4!&G'D<^/;LAO@>27R(_EDDF<F=\KWW0C_083#V<>L
M)M<+F!)1[I)+WJ?,(S]7X2%O"&\2@4@\$6GDLGI6U10Z2=QJG$3D!GD],EZ-
MG)Y?RW>=]BD'5)/3POG^*&CH5DFZJ?<OK3S#K(AD D]$DH@\,M P$<6Z29R$
MC/1"\1CW"<4KA+H/4BN58\W:_H '4AXBCQP> O&) =.D/28G#&JK-\R^1Q&+
MHVJZ(X7!T]D\:*R7_PR_>GCEJ0%OQI3K.YJQ.JA=X \*Q,<)\(90R:E3UDE
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M\9P!M,2=C9UQO_U9:=1KDBM0+^C32H,  H'X"'\)=1A,$<\;=-WCF1;@\1<
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MS=+)S24YOZ^2LR3,(FAQ,&TJA1&60'LR25LERZ:!4+,L19(TQ\IJ%@F!.JY
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MN E90+D[:CTLS3Y"-@AR)FQ[;TQ::&I&HVQO4G @M0!(.PP,7J>LL ^-RM?
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M8 -[>_I_VQ'N$/[IQP/OA_\/4$L! A0#%     @ KX#_6$CD:%/O%0  F)
M !$              ( !     '9N9&$M,C R-# W,S$N:'1M4$L! A0#%
M  @ KX#_6*\'+HU) P  * L  !$              ( !'A8  '9N9&$M,C R
M-# W,S$N>'-D4$L! A0#%     @ KX#_6+)'ODVF"   V#X  !4
M     ( !EAD  '9N9&$M,C R-# W,S%?9&5F+GAM;%!+ 0(4 Q0    ( *^
M_U@K5^J;W P  !YP   5              "  6\B  !V;F1A+3(P,C0P-S,Q
M7VQA8BYX;6Q02P$"% ,4    " "O@/]8"'D,8U0(  "Z00  %0
M    @ %^+P  =FYD82TR,#(T,#<S,5]P<F4N>&UL4$L! A0#%     @ KX#_
M6-O6KI%#*@  JPX" !P              ( !!3@  '9N9&$X+6LW,S$R,#(T
D97AH:6)I=#DY,2YH=&U02P4&      8 !@"1 0  @F(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>vnda-20240731_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:vnda="http://www.vandapharmaceuticals.com/20240731"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vnda-20240731.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <startDate>2024-07-31</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-31</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vnda:SeriesAJuniorParticipatingPreferredStockPurchaseRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-31</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001347178</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-26">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-07-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">VANDA PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-34186</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">03-0491827</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">2200 Pennsylvania Avenue NW</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 300E</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Washington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">DC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">20037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">202</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">734-3400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-2" id="f-18">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-19">VNDA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-21">Series A Junior Participating Preferred Stock Purchase Right, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-22">-</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-23">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-24">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
